FR2444031B1 - - Google Patents

Info

Publication number
FR2444031B1
FR2444031B1 FR7930438A FR7930438A FR2444031B1 FR 2444031 B1 FR2444031 B1 FR 2444031B1 FR 7930438 A FR7930438 A FR 7930438A FR 7930438 A FR7930438 A FR 7930438A FR 2444031 B1 FR2444031 B1 FR 2444031B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7930438A
Other versions
FR2444031A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp
Original Assignee
Pfizer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10501705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2444031(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Corp filed Critical Pfizer Corp
Publication of FR2444031A1 publication Critical patent/FR2444031A1/fr
Application granted granted Critical
Publication of FR2444031B1 publication Critical patent/FR2444031B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR7930438A 1978-12-13 1979-12-12 Nouveaux derives d'imidazole, leur procede de production et composition pharmaceutique les contenant Granted FR2444031A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7848367 1978-12-13

Publications (2)

Publication Number Publication Date
FR2444031A1 FR2444031A1 (fr) 1980-07-11
FR2444031B1 true FR2444031B1 (fr) 1983-06-10

Family

ID=10501705

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7930438A Granted FR2444031A1 (fr) 1978-12-13 1979-12-12 Nouveaux derives d'imidazole, leur procede de production et composition pharmaceutique les contenant

Country Status (34)

Country Link
US (2) US4602016A (fr)
JP (1) JPS585197B2 (fr)
KR (1) KR830001243B1 (fr)
AR (1) AR227637A1 (fr)
AT (1) AT373879B (fr)
AU (1) AU517892B2 (fr)
BE (1) BE880584A (fr)
CA (1) CA1108137A (fr)
CH (1) CH644597A5 (fr)
CS (1) CS216517B2 (fr)
DD (1) DD147943A5 (fr)
DE (1) DE2950019A1 (fr)
DK (1) DK471479A (fr)
EG (1) EG14227A (fr)
ES (1) ES486782A0 (fr)
FI (1) FI70888C (fr)
FR (1) FR2444031A1 (fr)
GB (1) GB2038821B (fr)
GR (1) GR73003B (fr)
HU (1) HU183016B (fr)
IE (1) IE49318B1 (fr)
IL (1) IL58917A (fr)
IT (1) IT1194900B (fr)
LU (1) LU81985A1 (fr)
NL (1) NL177749C (fr)
NO (1) NO153135C (fr)
NZ (1) NZ192360A (fr)
PH (1) PH15056A (fr)
PL (1) PL134005B1 (fr)
PT (1) PT70571A (fr)
SE (1) SE444937B (fr)
SU (1) SU878195A3 (fr)
YU (1) YU301879A (fr)
ZA (1) ZA796708B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350696A (en) 1980-03-08 1982-09-21 Pfizer Inc. Imidazole derivatives, process for their preparation and pharmaceutical compositions thereof
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
DE3148291A1 (de) * 1981-12-05 1983-06-09 Basf Ag, 6700 Ludwigshafen Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPS58113178A (ja) * 1981-12-28 1983-07-05 Yamanouchi Pharmaceut Co Ltd 「お」−（１−イミダゾリル）アルキルオキシ（またはチオ）ベンゼン誘導体
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
NL8301550A (nl) * 1983-05-03 1984-12-03 Gist Brocades Nv Imidazolethanol esters.
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
PH22076A (en) * 1983-08-25 1988-05-20 Daiichi Seiyaku Co Benzocycloalkane derivative
IT1212791B (it) * 1983-11-24 1989-11-30 Medea Res Srl Derivato imidazolico adattivita' vasodilatatrice ed antitrombotica, sua preparazione e composizioni farmaceutiche che lo contengono.
ES8601148A1 (es) * 1984-12-10 1985-11-16 Ferrer Int Procedimiento de obtencion de nuevos derivados imidazoliletoxiindanicos.
US4894385A (en) * 1985-01-16 1990-01-16 Sankyo Company Limited Imidazole derivatives as inhibitors of TXA2 synthesis
KR920002129B1 (ko) 1986-01-27 1992-03-12 상꾜 가부시끼가이샤 티아나프텐 유도체의 제조방법
DE3786030T2 (de) 1986-03-27 1993-12-02 Merck Frosst Canada Inc Tetrahydrocarbazole Ester.
JPS63179840A (ja) * 1986-07-24 1988-07-23 Yamanouchi Pharmaceut Co Ltd 新規化学物質
ATE57925T1 (de) * 1987-04-03 1990-11-15 Cl Pharma Neue 2-thienyloxyessigsaeurederivate, ein verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
JPH01125372A (ja) * 1988-09-12 1989-05-17 Yamanouchi Pharmaceut Co Ltd イミダゾリルアルキルオキシベンゼン誘導体
DE4204686A1 (de) * 1992-02-17 1993-08-19 Gruenenthal Gmbh Imidazolylphenolderivate, diese enthaltende arzneimittel sowie ein verfahren zur herstellung dieser verbindungen und arzneimitteln
AU2890899A (en) * 1998-03-13 1999-09-27 Pozen, Inc. Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists
ES2172436B1 (es) 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
JP2005533830A (ja) * 2002-07-09 2005-11-10 ビー．エム．アール．エイ． コーポレイション ベスローテン フェンノートシャップ トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ
JP2007508242A (ja) * 2003-08-07 2007-04-05 ビー．エム．アール．エイ． コーポレイション ベスローテン フェンノートシャップ トロンボキサンａ２受容体アンタゴニストとシクロオキシゲネーゼ−１の阻害剤との組み合わせを伴う組成物および方法
KR101275814B1 (ko) * 2006-06-23 2013-06-18 삼성에스디아이 주식회사 분산제 화합물 및 그의 제조방법
EP2234608A2 (fr) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage
CN101811974B (zh) * 2010-04-15 2012-12-12 合肥医工医药有限公司 4-(3-(二甲氨基)丙氧基)-3,5-二甲氧基苯甲酸、其制法及医药用途
CN101851209B (zh) * 2010-06-21 2012-09-19 合肥医工医药有限公司 咪唑乙基香草酸醚、其制备方法及其医药用途
EA026393B1 (ru) * 2012-05-22 2017-04-28 Дженентек, Инк. N-замещенные бензамиды и их применение в лечении боли
BR112015008987A2 (pt) 2012-10-26 2017-07-04 Merck Sharp & Dohme composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
WO2023240378A1 (fr) * 2022-06-13 2023-12-21 南京医工医药技术有限公司 Dérivé d'éther d'acide imidazolidinyl-vanillique et son utilisation
CN114736161B (zh) * 2022-06-13 2022-09-13 南京医工医药技术有限公司 咪唑烷基香草酸醚衍生物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3534061A (en) * 1967-12-04 1970-10-13 Parke Davis & Co N-(alpha-(p-methoxyphenyl)-beta-nitrostyryl)-phenoxyalkyl pyrroles
US4085209A (en) * 1975-02-05 1978-04-18 Rohm And Haas Company Preparation and safening effect of 1-substituted imidazole metal salt complexes
US4078071A (en) * 1976-03-08 1978-03-07 Syntex (U.S.A.) Inc. Derivatives of substituted N-alkyl imidazoles
JPS5951943B2 (ja) * 1978-08-21 1984-12-17 キツセイ薬品工業株式会社 新規なイミダゾ−ル誘導体

Also Published As

Publication number Publication date
SU878195A3 (ru) 1981-10-30
JPS5585572A (en) 1980-06-27
BE880584A (fr) 1980-06-12
AU5372579A (en) 1980-06-19
SE444937B (sv) 1986-05-20
IT7941669A0 (it) 1979-12-11
NZ192360A (en) 1982-02-23
ES8101556A1 (es) 1980-12-16
PT70571A (en) 1980-01-01
AT373879B (de) 1984-02-27
ES486782A0 (es) 1980-12-16
US4602016A (en) 1986-07-22
DK471479A (da) 1980-06-14
NO794069L (no) 1980-06-16
JPS585197B2 (ja) 1983-01-29
AU517892B2 (en) 1981-09-03
PL134005B1 (en) 1985-07-31
DD147943A5 (de) 1981-04-29
NO153135C (no) 1986-01-22
FI793868A (fi) 1980-06-14
NL177749B (nl) 1985-06-17
PH15056A (en) 1982-06-03
NO153135B (no) 1985-10-14
CS216517B2 (en) 1982-11-26
KR830001243B1 (ko) 1983-06-27
CH644597A5 (de) 1984-08-15
IE792403L (en) 1980-06-13
CA1108137A (fr) 1981-09-01
FR2444031A1 (fr) 1980-07-11
FI70888C (fi) 1986-10-27
LU81985A1 (fr) 1980-04-22
IT1194900B (it) 1988-09-28
GB2038821A (en) 1980-07-30
ATA783379A (de) 1983-07-15
AR227637A1 (es) 1982-11-30
ZA796708B (en) 1981-08-26
DE2950019A1 (de) 1980-07-10
IL58917A (en) 1984-03-30
IE49318B1 (en) 1985-09-18
GB2038821B (en) 1982-12-08
IL58917A0 (en) 1980-03-31
YU301879A (en) 1983-01-21
EG14227A (en) 1983-12-31
HU183016B (en) 1984-04-28
PL220351A1 (fr) 1980-12-01
FI70888B (fi) 1986-07-18
US4636500A (en) 1987-01-13
KR830001242A (ko) 1983-04-29
GR73003B (fr) 1984-01-24
NL7908899A (nl) 1980-06-17
SE7910204L (sv) 1980-06-14
NL177749C (nl) 1985-11-18

Similar Documents

Publication Publication Date Title
FR2416747B1 (fr)
AU3898778A (fr)
AU73950S (fr)
BG26013A1 (fr)
BG26015A1 (fr)
BE871570A (fr)
BG25806A1 (fr)
BG25814A2 (fr)
BG25816A1 (fr)
BG25818A1 (fr)
BG25835A1 (fr)
BG25836A1 (fr)
BG25842A1 (fr)
BG25843A1 (fr)
BG25849A1 (fr)
BG25854A1 (fr)
BG25857A1 (fr)
BG25858A1 (fr)
BG25871A1 (fr)
BG25872A1 (fr)
BG25874A1 (fr)
BG25875A1 (fr)
BG25879A1 (fr)
BG25889A1 (fr)
BG26014A1 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse